Acurx Pharmaceuticals Inc... (ACXP)
0.68
-0.03 (-4.16%)
At close: Mar 03, 2025, 3:59 PM
0.68
-0.86%
After-hours: Mar 03, 2025, 07:39 PM EST
No 1D chart data available
| Bid | 0.67 |
| Market Cap | 13.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.38B |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.38 |
| Analyst | Buy |
| Ask | 0.7 |
| Volume | 134,359 |
| Avg. Volume (20D) | 358,658 |
| Open | 0.70 |
| Previous Close | 0.71 |
| Day's Range | 0.67 - 0.71 |
| 52-Week Range | 0.67 - 3.33 |
| Beta | -1.72 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bac...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ACXP
Website https://www.acurxpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ACXP stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1657.47% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
-26.01%
Acurx Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
1 month ago
+22.49%
Acurx Pharmaceuticals shares are trading higher after the company announced the European Medical Agency (EMA) granted positive regulatory guidance for its Ibezapolstat Phase 3 program for C. Difficile Infection.
